The incidence of creatinine-defined AKI was greater in the rosuvastatin group than in the placebo group (24.7% vs. 19.3%, OR 1.37, 95% CI 1.10–1.70, P = .005; Figure 1A)1, as was the incidence of cystatin C–defined AKI (9.2% vs. 5.1%, OR 1.86, 95% CI 1.29–2.67, P < .001; Figure 1B). The gene discussed is CST3; the disease is acute kidney injury.